The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
Lysyy T, Lalani AS, Olek EA, Diala I, Geibel JP. The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea. Pharmacology Research & Perspectives 2019, 7: e00521. PMID: 31523434, PMCID: PMC6743423, DOI: 10.1002/prp2.521.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsCaSR activationCalcium-sensing receptorDose-dependent mannerFluid secretionRat intestineHER2-positive breast cancerKinase inhibitorsAdverse effectsChemotherapy-associated diarrheaNeratinib-induced diarrheaCommon side effectsIsolated intestinal segmentsPotent therapeutic targetIrreversible panPatients' qualityBreast cancerIntestinal segmentsSide effectsTherapeutic targetDiarrheaPronounced elevationIntraluminal calcium concentrationVivo modelNeratinibDesign and implementation of novel nutraceuticals and derivatives for treating intestinal disorders
Barahona MJ, Baratta V, Ollodart J, Mulligan D, Geibel JP. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future Medicinal Chemistry 2019, 11: 847-855. PMID: 30994367, PMCID: PMC8008207, DOI: 10.4155/fmc-2018-0313.Peer-Reviewed Original ResearchConceptsSignificant worldwide disease burdenSpectrum of illnessWorldwide disease burdenIntestinal fluid secretionSystemic side effectsCalcium-sensing receptorNovel therapeutic targetG protein-coupled receptorsSurgical therapyPharmaceutical optionsMucosal integrityDisease burdenIntestinal disordersNutraceutical therapyGastrointestinal diseasesGastrointestinal illnessSide effectsTherapeutic targetFluid secretionIntestinal cellsTherapyAdverse effectsNovel nutraceuticalsCaSRIllness